



SAFETY DATA SHEET

Revision date 17-Jun-2025

Version 4

Page 1 / 14

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Metronidazole Injection (Hospira, Inc.)
Product Code(s) PZ03211
Trade Name: FLAGYL
Chemical Family: Mixture

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as antiprotozoal agent

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: Regulated according to Regulation (EC) 1272/2008 and/or other applicable regulations.

Germ cell mutagenicity Category 1B - (H340)
Carcinogenicity Category 1B - (H350)
Reproductive toxicity Category 2 - (H361d)

OSHA Classification

Hazards not otherwise classified (HNOC)

Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200

Not applicable

SAFETY DATA SHEET

Product Name Metronidazole Injection (Hospira, Inc.)
Revision date 17-Jun-2025

Page 2 / 14
Version 4

2.2. Label elements



Signal word

Danger

Hazard statements

H350 - May cause cancer
H340 - May cause genetic defects
H361d - Suspected of damaging the unborn child
OSHA - May form combustible dust concentrations in air

Precautionary Statements - EU (§28, 1272/2008)

P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical advice/attention
P405 - Store locked up
P501 - Dispose of contents/container in accordance with local, regional, national, and international regulations as applicable

2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Metronidazole (CAS #: 443-48-1)	0.5		207-136-1	Carc. 1 (H350) Repr. 2 (H361d)	Not classified	No data available	No data available

SAFETY DATA SHEET

Product Name Metronidazole Injection (Hospira, Inc.)
Revision date 17-Jun-2025

Page 3 / 14
Version 4

				Muta.1B (H340)			
Citric acid (CAS #: 77-92-9)	< 0.1		201-069-1 (607-750-00-3)	Eye Irrit. 2A (H319)SE 3 (H335)	Not classified	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified	Not classified	No data available	No data available
SODIUM CHLORIDE (CAS #: 7647-14-5)	*	-	231-598-3	Not classified	Not classified	No data available	No data available
Sodium phosphate, dibasic (CAS #: 7558-79-4)	*		231-448-7	Not classified	Not classified	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3550	10000	No data available	No data available	No data available
Sodium phosphate, dibasic 7558-79-4	17000	No data available	No data available	No data available	No data available
Metronidazole 443-48-1	3000	No data available	No data available	No data available	No data available
Citric acid 77-92-9	5400	>2000	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration $\geq 0.1\%$ (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Additional information

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation

Remove to fresh air. Seek immediate medical attention/advice.

Eye contact

Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.

SAFETY DATA SHEET

Product Name Metronidazole Injection (Hospira, Inc.)
Revision date 17-Jun-2025

Page 4 / 14
Version 4

Skin contact Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Not applicable.

Hazardous combustion products Formation of toxic gases is possible during heating or fire.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

SAFETY DATA SHEET

Product Name Metronidazole Injection (Hospira, Inc.)
Revision date 17-Jun-2025

Page 5 / 14
Version 4

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions

Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s)

Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Metronidazole

Pfizer OEL TWA-8 Hr: 700 µg/m³

SODIUM CHLORIDE

Latvia

TWA: 5 mg/m³;

Russia

MAC: 5 mg/m³

Sodium phosphate, dibasic

Russia

MAC: 10 mg/m³

Metronidazole

Germany TRGS

DS

RS

Netherlands

TWA: 0.00012 mg/m³;

Russia

MAC: 1 mg/m³

Citric acid

Czech Republic

4 mg/m³

Germany DFG

TWA-MAK: 2 mg/m³; I(2);inhalable fraction

Peak: 4 mg/m³; respirable fraction

Germany TRGS

TWA-AGW; 2 mg/m³ (exposure factor 2); inhalable fraction

Russia

MAC: 1 mg/m³

Switzerland

TWA-MAK: 2 mg/m³; inhalable dust

STEL-KZGW: 4 mg/m³; inhalable dust

Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based

SAFETY DATA SHEET

Product Name Metronidazole Injection (Hospira, Inc.)
Revision date 17-Jun-2025

Page 6 / 14
Version 4

upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

SODIUM CHLORIDE

Pfizer Occupational Exposure
Band (OEB):

OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

8.2. Exposure controls

Engineering controls

General room ventilation is adequate unless the process generates dust, mist or fumes. Engineering controls should be used as the primary means to control exposures. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

Thermal hazards

No information available.

Environmental exposure controls

No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state

Liquid

Color

No information available

Odor

No information available.

Odor threshold

No information available

Property

Values

Melting point / freezing point

No data available

Boiling point or initial boiling point and boiling range

No data available

SAFETY DATA SHEET

Product Name Metronidazole Injection (Hospira, Inc.)
Revision date 17-Jun-2025

Page 7 / 14
Version 4

Flammability (solid, gas)	No data available
Lower and upper explosion limit/flammability limit	
Lower explosion limit	No data available
Upper explosion limit	No data available
Flash point	No data available
Autoignition temperature	No data available
Decomposition temperature	
SADT (°C)	No data available
pH	4.5-7.0
pH (as aqueous solution)	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Solubility	No data available
Vapor pressure	No data available
Density and/or relative density	No data available
Bulk density	No data available
Liquid Density	No data available
Vapor density	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available

9.2. Other information

Molecular formula	Mixture
Molecular weight	Mixture

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity	No information available.
------------	---------------------------

10.2. Chemical stability

Stability	Stable up to .?°C.
-----------	--------------------

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions	No information available.
------------------------------------	---------------------------

10.4. Conditions to avoid

Conditions to avoid	Fine particles (such as mists) may fuel fires/explosions.
---------------------	---

10.5. Incompatible materials

Incompatible materials	As a precautionary measure, keep away from strong oxidizers.
------------------------	--

10.6. Hazardous decomposition products

Hazardous decomposition products	No data available.
----------------------------------	--------------------

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

SAFETY DATA SHEET

Product Name Metronidazole Injection (Hospira, Inc.)
Revision date 17-Jun-2025

Page 8 / 14
Version 4

General Information:	The information included in this section describes the potential hazards of the individual ingredients
Short term	Ingestion of large amounts may cause central nervous system effects.
Long Term:	Animal studies have shown a potential to cause adverse effects on the fetus. Suspected of causing cancer
Known Clinical Effects:	Clinical use of this drug has caused peripheral neuropathy, associated with numbness and tingling of the extremities, pain, and motor weakness. Effects on blood and blood-forming organs have also occurred.
Acute toxicity	Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation	Based on available data, the classification criteria are not met.
Skin corrosion/irritation	Based on available data, the classification criteria are not met.
Respiratory or skin sensitization	Based on available data, the classification criteria are not met.
STOT - single exposure	Based on available data, the classification criteria are not met.
STOT - repeated exposure	Based on available data, the classification criteria are not met.
Reproductive toxicity	Suspected of damaging the unborn child. Classification is based on mixture calculation methods based on component data.
Germ cell mutagenicity	May cause genetic defects. Classification is based on mixture calculation methods based on component data.
Carcinogenicity	May cause cancer. Classification is based on mixture calculation methods based on component data.
Aspiration hazard	Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³
Rat Oral LD 50 3 g/kg
Mouse Oral LD 50 4 g/kg
Rabbit Dermal LD 50 > 10 g/kg

Metronidazole

Rat Oral LD 50 5000 g/kg
Mouse Oral LD 50 4350 mg/kg
Mouse Intraperitoneal LD 50 3650 mg/kg

Citric acid

Mouse Oral LD50 5400 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
SODIUM CHLORIDE	= 3550 mg/kg (Rat)	> 10000 mg/kg (Rabbit)	> 42 mg/L (Rat) 1 h
Sodium phosphate, dibasic	= 17 g/kg (Rat)	-	-
Metronidazole	= 3 g/kg (Rat)	-	-
Citric acid	= 3 g/kg (Rat)	> 2000 mg/kg (Rat)	-

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin irritation Rabbit Mild
Eye irritation Rabbit Mild

Metronidazole

SAFETY DATA SHEET

Product Name Metronidazole Injection (Hospira, Inc.)
Revision date 17-Jun-2025

Page 9 / 14
Version 4

Eye Irritation Rabbit No effect

Citric acid

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Metronidazole

4 Week(s) Rat Oral 50 mg/kg/day NOAEL None identified

4 Week(s) Dog Oral 50 mg/kg/day NOAEL None identified

4 Week(s) Rat Intravenous 30 mg/kg/day LOAEL Thyroid

4 Week(s) Dog Intravenous 37.5 mg/kg/day LOAEL Thyroid

13 Week(s) Rat Oral 75 mg/kg/day LOAEL Male reproductive system

14 Week(s) Monkey Oral 45 mg/kg/day LOAEL Liver

17 Week(s) Dog Oral 75 mg/kg/day LOAEL Central Nervous System

6 Month(s) Dog Oral 75 mg/kg/day LOAEL Central Nervous System

Repeated Dose Toxicity Comments: Metronidazole produced tumors in mice and rats.

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Metronidazole

Reproductive & Fertility Rat Oral 400 mg/kg LOAEL Fertility

Reproductive & Fertility Rabbit Oral 200 mg/kg NOAEL Fertility, Developmental toxicity, Fetotoxicity

Embryo / Fetal Development Mouse Intraperitoneal 15 mg/kg/day LOAEL Embryotoxicity

Embryo / Fetal Development Rat Oral 200 mg/kg/day NOAEL Not Teratogenic

Embryo / Fetal Development Rabbit Oral 150 mg/kg/day NOAEL No effects at maximum dose

Embryo / Fetal Development Rat Intravenous 30 mg/kg/day NOAEL Embryotoxicity

Embryo / Fetal Development Rabbit Intravenous 15 mg/kg/day LOAEL Embryotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Metronidazole

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Positive

In Vivo Micronucleus Mouse Positive

In Vivo Unscheduled DNA Synthesis Rabbit Human / Rat Hepatocyte Positive

Dominant Lethal Assay Rat Negative

In Vivo Comet DNA Damage Human Lymphocytes Positive

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Metronidazole

78 Week(s) Mouse Oral, in feed 150 mg/kg/day NOAEL Tumors

80 Week(s) Rat Oral 150 mg/kg/day NOAEL Tumors

92 Week(s) Mouse Oral, in feed 150 mg/kg/day NOAEL Tumors

Not specified Rat Oral, in feed 150 mg/kg/day NOAEL Tumors

Carcinogenicity See below

Metronidazole

IARC Group 2B

NTP Reasonably Anticipated

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

11.2.2. Other information

Other adverse effects No information available.

SAFETY DATA SHEET

Product Name Metronidazole Injection (Hospira, Inc.)
Revision date 17-Jun-2025

Page 10 / 14
Version 4

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties of the formulation have not been thoroughly investigated.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Metronidazole

Mysidopsis bahia (Mysid Shrimp) OECD LC50 96 hours > 180 mg/L
Cyprinodon variegatus (Sheepshead Minnow) OECD LC-50 96 hours > 1060 mg/L
Pseudokirchneriella subcapitata (Green Alga) ISO EC50 72 hours 39.1 mg/L
Chlorella spp Green Alga ISO EC50 72 hours 12.5 mg/L
Brachydanio rerio (Zebra fish) ISO NOEC 96 hours 500 mg/L

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Metronidazole

Activated sludge OECD EC50 100 mg/L

Metronidazole

Daphnia magna (Water Flea) N/A 21 Day(s) NOEC 250 mg/L Reproduction

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
SODIUM CHLORIDE	Not PBT/vPvB PBT assessment does not apply
Sodium phosphate, dibasic	PBT assessment does not apply
Citric acid	Not PBT/vPvB

12.6. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

12.7. Other adverse effects

Other adverse effects No information available.

PMT or vPvM properties Based on available data, the classification criteria are not met.

Section 13: DISPOSAL CONSIDERATIONS

SAFETY DATA SHEET

Product Name Metronidazole Injection (Hospira, Inc.)
Revision date 17-Jun-2025

Page 11 / 14
Version 4

13.1. Waste treatment methods

Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:	Not applicable
UN proper shipping name:	Not applicable
Transport hazard class(es):	Not applicable
Packing group:	Not applicable
Environmental Hazard(s):	Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present

SODIUM CHLORIDE

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-598-3
AICS	Present

Sodium phosphate, dibasic

CERCLA/SARA Section 313 de minimus %	Not Listed
Hazardous Substances RQs	5000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-448-7
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6

Metronidazole

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Carcinogen

SAFETY DATA SHEET

Product Name Metronidazole Injection (Hospira, Inc.)
Revision date 17-Jun-2025

Page 12 / 14
Version 4

EINECS	207-136-1
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 4
Citric acid	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	201-069-1
AICS	Present

National regulations

France

Occupational Illnesses (R-463-3, France)

Chemical name	French RG number
SODIUM CHLORIDE 7647-14-5	RG 78

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)

Not applicable

TRGS 905

Not applicable

Chemical name	Netherlands - List of Carcinogens	Netherlands - List of Mutagens	Netherlands - List of Reproductive Toxins
Metronidazole 443-48-1	Present	-	-

Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018 Not applicable

Storage of Hazardous Material

Not applicable

WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20

Not applicable

Major Accidents Ordinance SR 814.012

Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Citric acid 77-92-9	75	-

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

EU - Plant Protection Products (1107/2009/EC)

SAFETY DATA SHEET

Product Name Metronidazole Injection (Hospira, Inc.)
Revision date 17-Jun-2025

Page 13 / 14
Version 4

Chemical name	EU - Plant Protection Products (1107/2009/EC)
SODIUM CHLORIDE 7647-14-5	Plant protection agent
Chemical name	Biocidal Products Regulation (EU) No 528/2012 (BPR)
SODIUM CHLORIDE 7647-14-5	Product-type 1: Human hygiene
Citric acid 77-92-9	Product-type 2: Disinfectants and algacides not intended for direct application to humans or animals Product-type 6: Preservatives for products during storage

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDL - Canadian Domestic Substances List/Non-Domestic Substances List
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
ENCS - Japan Existing and New Chemical Substances
IECSC - China Inventory of Existing Chemical Substances
KECL - Korean Existing Chemicals Inventory
PICCS - Philippines Inventory of Chemicals and Chemical Substances
AICS - Australian Inventory of Chemical Substances
NZIoC - New Zealand Inventory of Chemicals
TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H350 - May cause cancer. H361d - Suspected of damaging the unborn child. H319 - Causes serious eye irritation. H340 - May cause genetic defects.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 15 - Regulatory Information. Updated Section 16 - Other Information.

Revision date 17-Jun-2025

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there

SAFETY DATA SHEET

Product Name Metronidazole Injection (Hospira, Inc.)
Revision date 17-Jun-2025

Page 14 / 14
Version 4

is no known information at this time.